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Abstract
Purpose The level of drug metabolism and drug transport
is correlated with the sensitivity of cancer cells towards
platinum-based chemotherapy. We hypothesize that genetic
polymorphisms in metabolising enzymes gene GSTP1
(glutathione  S-transferase P1), and MRP2 (multidrug
resistance-associated protein 2) (ABCC2), which result in
inter-individual diVerences in metabolism and drug disposi-
tion, may predict clinical response to platinum agents in
advanced non-small cell lung cancer (NSCLC) patients.
Methods Totally 113 patients with advanced NSCLC
were routinely treated with platinum-based chemotherapy,
and clinical response was evaluated after four cycles.
MRP2 C-24T (¡24C>T), MRP2 Val417Ile (1249G>A),
MRP2 Ile1324Ile (3972C>T), and GSTP1 Ile105Val
(342A>G) genotype were determined by gene-chip method
(a 3-D (three dimensions) polyacrylamide gel-based DNA
microarray method) using DNA samples isolated from
peripheral blood collected before treatment. Pearson
Chi-square test and Fisher’s exact test were performed to
measure the diVerences of the chemotherapeutic eYcacy
among variant genotype. The odds ratios and 95% conW-
dence intervals were computed by logistic regression.
Results The C!T change of MRP2 C-24T and the A!G
change of GSTP1 Ile105Val polymorphism signiWcantly
increased platinum-based chemotherapy response.
Conclusion The polymorphic status of MRP2 C-24T and
GSTP1 Ile105Val might be the predictive markers for the
treatment response of advanced NSCLC patients. The DNA
microarray-based method is accurate, high throughput and
inexpensive, suitable for single-nucleotide polymorphism
genotyping in a large number of individuals.
Keywords Single-nucleotide polymorphism · Gene chip · 
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Introduction
Lung cancer is the most common cause of cancer death in
many countries; more than a million people in the world die
from the disease each year [1]. About 80% of lung cancer
patients are diagnosed with non-small cell lung cancer
(NSCLC), of which nearly two-thirds are detected at
advanced stages [2]. Chemotherapy is the major treatment
method currently for advanced NSCLC, but the rate of
eYcacy with standard cytotoxic chemotherapy is only 30–
40%, and this level has reached a “therapeutic plateau” [3].
At present, platinum-based double-agent therapies are the
major remedial measure of the advanced NSCLC and have
been shown to improve the overall survival [4]. Cisplatin is
still the scaVolding of combination chemotherapy.
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Resistance to chemotherapy is also a challenge. Cisplatin
resistance can develop as a result of decreased inXux or
increased eZux of drug, glutathione or metallothionein
conjugation, drug detoxiWcation, DNA repair, or skipping
lesions during DNA replication [5]. It is more likely that
the combination of these mechanisms results in the cis-
platin resistance. Because drug resistance varies from per-
son to person, genetic factors are believed to inXuence the
eVectiveness of lung cancer treatment [6].
The Wnding of human genome project indicated that 99%
of DNA within diVerent individuals were identical, and
only 1% was variant, of which the major one was single-
nucleotide polymorphism (SNP). SNP is a point mutation
carried by some individuals of a population. The study of
pharmacogenetics indicated that such tiny diversity in
sequence of genome signiWcantly inXuenced on individual
treatment response, toxicity, and survival in cancer patients.
Because the inter-individual variation is necessary for the
optimization of medication, the genetic polymorphisms
have the potential signiWcance in drug disposition and phar-
macokinetics. In addition, SNP has greater clinical signiW-
cance in terms of its ease of clinical application, rather than
its mRNA, which present some clinical diYculties in terms
of obtaining tissue samples from lung cancer patients.
As known, platinum-based drugs inhibit tumor growth
mainly by the formation of bulky DNA adducts, and the lat-
ter are mainly removed by DNA repair mechanisms, espe-
cially by the nucleotide excision repair (NER) mechanisms.
Also, our work team has already done some work about the
association of DNA repair gene polymorphisms and plati-
num-based chemotherapy. Moreover, it should not been
disregarded that drug metabolism and drug transport also
play an important role in response to platinum-based che-
motherapy.
Phase II metabolising enzymes take advantage of elec-
trophilic groups intrinsically carried in a structure, or intro-
duced by phase I metabolism, to conjugate xenobiotics with
donor molecules, such as glutathione (GSH), UDP glucu-
ronic acid, or 3-phosphoadenosine-5- phosphosulfate
(PAPS). The glutathione S-transferase (GST) family of
phase II metabolizing enzymes catalyzes detoxifying
endogenous reactions with GSH and protect cellular macro-
molecules from damage caused by a wide variety of endog-
enous and exogenous molecules, including cytotoxic,
mutagens, carcinogens, and chemotherapeutic agents [7].
The resulting glutathione adducts have increased the solu-
bility and can then be either excreted or further metabo-
lized. In the current lung cancer chemotherapy, many of the
commonly used drugs are metabolized by the glutathione
system, especially the platinum drugs [8].
The 17 human cytosolic GST subunits are classiWed as
seven gene families according to their biochemical charac-
teristics and amino acid sequence similarities:  (GSTA),
 (GSTM),  (GSTT),  (GSTP),  (GSTO),  (GSTZ),
and  (GSTS) [9]. Human GSTs are nearly ubiquitously
expressed, and GSTP is the most abundant subunit in lung
and brain. GSTP1 is widely expressed in diVerent human
epithelial tissue [10] and is the most abundant GST isoform
in the lung [11]. GSTP1 conjugates and protects particu-
larly against the cytotoxic eVects of some chemotherapeutic
agents, including anthracyclines, alkylating agents, and
their metabolites [12]. The GST gene families, including
glutathione S-transferase P1 (GSTP1), contain several poly-
morphic loci. At least three of the genes that code for GSTs,
GSTM1, GSTT1, and GSTP1, have been found to have
functional polymorphisms that are frequently present in
general populations [13]. The role of GSTs in the detoxiW-
cation of antitumor agents suggests the possible implication
of GST polymorphisms to the chemotherapeutic response.
Patients with a GSTs-null genotype are believed to exhibit
impaired detoxiWcation of environmental genotoxic agents
and chemotherapeutic drugs, which prompts the hypothesis
that allelic variants associated with less eVective detoxiWca-
tion of potential antitumor drugs can confer an increased
sensitivity to chemotherapy.
In addition to the enzyme, drug transporters are impor-
tant in determining drug absorption, drug distribution to tis-
sues, and drug excretion in the urine and bile. Some studies
have shown that the conjugates formed by GSTs are trans-
ported by MRP2 (multidrug resistance protein 2, also des-
ignated canalicular multispeciWc organic anion transporter,
cMOAT, or ABCC2 protein), which are the part of the
phase III biotransformation system, in an ATP-dependent
manner [14, 15]. Furthermore, GSTP1 activity may work
synergistically with MRP transport as a tri-GSH conjugate
[16].
Multidrug resistance-associated protein 2 are expressed
in the outer plasma membrane as well as in intracellular
vesicles and the Golgi apparatus. This indicates a role in the
sequestration of drugs into vesicles and cellular drug
export. The human MRP subfamily contains nine members.
MRP2 is a 1,545 amino acid, 190–200 kDa protein having
two ATP-binding domains, and 17 transmembrane regions
in its sequence [17]. MRP2 belongs to the subfamily C of
ABC (ATP-binding cassette) transporter proteins [18], the
eZux transporters that have a role in limiting inXux and
facilitating eZux to prevent the intracellular accumulation
of their own substrate compounds [17]. Drugs are detoxi-
Wed and conjugated in vivo and then exported out of the
cells. In tumor cells, such functions confer multidrug resis-
tance for various anticancer agents. MRP2 has broad-sub-
strate speciWcity and was identiWed to transport relatively
hydrophilic compounds, including the glucuronide, gluta-
thione, and sulfate conjugates of endogenous and exoge-
nous compounds covering organic anions derived from
phases I and II metabolism of xenobiotics and anionicCancer Chemother Pharmacol (2010) 65:437–446 439
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anticancer drugs, such as cisplatin [19, 20]. The interindi-
vidual variations on activity and expression level of the
transporter, due to SNP of MRP2 gene, might be a critical
factor in selection of the anticancer drugs.
It has been speculated that SNPs in drug metabolizing
enzymes genes and drug transporters genes may alter their
expression or activity, aVect drug disposition, and in turn
inXuence the eVects of cancer treatment [21]. Therefore, we
could expect that the lower the levels of expression of
GSTP1 and MRP2, the more susceptible the tumors to plat-
inum therapies. Here, a study of 113 NSCLC patients was
conducted to evaluate if functional polymorphisms in
GSTP1 and MRP2 are associated with patient response to
chemotherapy.
Patients and methods
Study subjects
All patients for the study were recruited from several hospi-
tals in Nanjing of China between March 2006 and Septem-
ber 2007. To avoid the confounding eVect of diVerences in
outcome resulting from clinical stage, only advanced
NSCLC patients were included in the analysis. Because
SNPs evaluated in the present study are potentially relevant
to therapies based on platinum, only the response to the Wrst
platinum-based regimen was assessed, and the patients who
had received previous chemotherapy were excluded. There
were 113 patients who were eligible in this study. These
113 eligible patients, all of Chinese Han people, were diag-
nosed with histologically conWrmed advanced NSCLC
(stages IIIA–IV), and had a measurable lesion by CT scan,
a Karnofsky performance status of not less than 60. The
status of all patients in electrocardiogram, blood chemis-
tries, hepatic, and renal function at the beginning of treat-
ment was normal. The study was approved by an Ethics
Review Committee at the hospital and patients gave con-
sent to participate. The main characteristics of patients were
shown in Table 1.
Chemotherapy regimens and therapeutic eVect evaluation
All patients had received platinum-based chemotherapy, 49
(43.4%) were given TP/TC/DP/DC regimens (DDP/
CBP+TAX/TXT/DOC), 59 (52.2%) had GP/GC regimens
(DDP/CBP+GEM), and 5 (4.4%) received NP/NC regi-
mens (DDP/CBP+NVB) (Table 1). Concrete dosage: DDP
(cisplatin) 30 mg/m2 on day 2–4; CBP (carboplatin)
AUC = 4–5 g on day 1; TAX (taxol/paclitaxel) 175 mg/m2
on day 1 (kept for 3 h), TXT (taxetere)/DOC (docetaxel)
75 mg/m2 on day 1 (kept for 1 h); GEM (gemcitabine)
1g / m 2 on day 1 and day 8; NVB (vinorelbine) 25 mg/m2 on
days 1 and 8. All chemotherapeutic drugs were adminis-
tered intravenously, and the treatment cycles were repeated
every 3–4 weeks. Patient responses to treatment were deter-
mined after four cycles by the WHO criteria [22], which
classify the response into four categories: complete
response (CR), partial response (PR), stable disease (SD),
and progressive disease (PD). CR was deWned as complete
disappearance of all measurable lesions. PR required at
least 50% reduction in measurable lesions. Patients with
SD had less than a 50% decrease or no more than a 25%
increase in the size of measurable lesions. PD was assigned
to patients when measurable lesions increased by more than
25% or new lesions appeared. For data analysis, CR and PR
were combined as responders, and SD and PD were
grouped as non-responders.
DNA collection and genotyping
Each patient provided 5 ml pretreatment blood for the
study. The blood samples were collected in citric acid/
EDTA anticoagulation tubes and stored at ¡80°C until
analysis. Genomic DNA was isolated from the blood sam-
ples using QIAGEN DNA mini Kit (China), and stored at
4°C until use.
Single-nucleotide polymorphisms were analyzed with
a 3-D polyacrylamide gel-based DNA microarray geno-
typing method. This method was invented by researchers
of State Key Laboratory of Bioelectronics, Southeast Uni-
versity in 2005 (Patent code: 200510040597.3) [23].
Probes and primers were designed by Primer Premier 5.0
Software. The sequences of primers and probes are shown
in Table 2. One of each pair primers was modiWed with
Table 1 Patient clinicopathologic characteristics and chemotherapy
regimens
DDP cisplatin, CBP carboplatin, TAX taxol/paclitaxel, TXT taxetere,
DOC docetaxel, GEM gemcitabine, NVB vinorelbine
Characteristics Patient no. (%)
Age (years)
Median (range) 59.6 (34-84)
Gender
Female 37 32.7
Male 76 67.3
Histology
Squamous cell carcinoma 30 26.5
Adenocarcinoma 80 70.8
Large cell and 
undiVerentiated carcinoma
32 . 7
Chemotherapy regimens
DDP/CBP+TAX/TXT/DOC 49 43.4
DDP/CBP+GEM 59 52.2
DDP/CBP+NVB 5 4.4440 Cancer Chemother Pharmacol (2010) 65:437–446
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acrylamide phosphoramidite (Acrydite™; Matrix Tech-
nologies) at its 5-terminal. Each couple of probes was
labeled with Cy3 and Cy5 Xuorescent dyes at 5-terminal
respectively. The PCR reactions were performed in 30 l
reaction solution containing 10 pmol primer and 50 ng
genomic DNA. The PCR reaction consisted of an initial
step at 95°C for 5 min, then 35–40 cycles of denaturing at
94°C for 30 s, annealing at 48–60°C (according to Tm) for
30 s and extension at 72°C for 40 s, and a last extension at
72°C for 5 min.
After PCR ampliWcation and gel electrophoresis test,
PCR products were processed by ethanol precipitation,
evaporation, or left untreated. Solutions containing acryl-
amide-modiWed PCR products, glycerol, ammonium per-
sulfate (APS), and acrylamide monomers were prepared,
spotted, and polymerized onto the acryl-modiWed slide.
In the process, TEMED is introduced onto the spotted
microarray to immobilize the modiWed nucleic acids.
Following the attachment to obtain ssDNA for hybridiza-
tion analysis, dsDNA on the slides was denatured in
0.1 M NaOH for 10 min. After hybridization, the slide
was subjected to electrophoresis under 5–30 V/cm for 5–
20 min in 1£ Tris–Borate–EDTA (TBE) buVer at 4°C.
Images of the slides were captured by a scanner
(LuxScan™-10 K Confocal Scanner, Packard BioSci-
ence Company, USA) and were analyzed with Genepix
Pro 3.0 Software. Sequencing of 10% samples was per-
formed to validate the results.
Statistical analysis
Statistical analysis was performed using SPSS Software
Package Version 13.0 (SPSS Inc., Chicago, IL, USA).
The signiWcance of diVerences in frequencies and geno-
types between good and poor responders was calculated
using the 2 test. 2 test was also performed to test for
Hardy–Weinberg equilibrium (HWE), haplotype fre-
quencies and haplotype-trait association. Continuity
correction test or Fisher’s exact test was performed
when >20% cells have expected count <5, but not <1,
and n > 40, or when theoretical frequency had expected
count <1 or n < 40. Multivariate analyses were per-
formed with the use of unconditional logistic regression
analysis to assess the association between treatment
response and each genetic polymorphism while adjust-
ing for patient gender, age at diagnosis, tumor histology,
disease stage, and chemotherapy regimens. The logistic
regression model was used to calculate the OR and their
95% CI. In the regression analysis, the outcome variable
was patient response to treatment; patients who had poor
respond to treatment (SD+PD) were compared with good
responders (CR+PR). All P values reported were two-
sided, and P values <0.05 were considered statistically
signiWcant.
Table 2 Sequences of primers 
and probes
Locus Primers and probes
MRP2 Forward primer: 5-CCTTTACGGAGAACATCAGA-3
(C-24T, rs717620) Reverse primer: 5-Acrydite™-TTTGCATTACATTTCCCAGA-3
Probe: 5-Cy3-AGTCTTCGTTCCA-3
           5-Cy5-AGTCTTTGTTCCA-3
MRP2 (Val 417 Ile) Forward primer: 5-TGGAGGCAAGAAGTCACAGT-3
(G1249A, rs2273697) Reverse primer: 5-Acrydite™-GATTACAAGCACCATCACCC-3
Probe: 5-Cy3-TACACCGTTGGAG-3
           5-Cy5-TACACCATTGGAG-3
MRP2 (Ile 1,324 Ile) Forward primer: 5-Acrydite™-CACTGCTACCCTTCTCCTGTTC-3
(C3972T, rs3740066) Reverse primer: 5-CTGACCCTTTCCCTCCATCC-3
Probe: 5-Cy3-GCTACCGATGTCA-3
           5-Cy5-GCTACCAATGTCA-3
GSTP1 (Ile 105 Val) Forward primer: 5-CAGGGCTCTATGGGAAGGAC-3
(A342G, rs1695) Reverse primer: 5-Acrydite™-CAGGAGATCAGAAACCACCAGTT-3
Probe: 5-Cy3-AAATACATCTCCC-3
           5-Cy5-AAATACGTCTCCC-3
Fig. 1 Microarray hybridization scanning patterns of SNPs genotyping.
A, B, C and D the microarray images of locus MRP2 C-24T, MRP2
Val417Ile, MRP2 Ile1324Ile and GSTP1 Ile105Val; green, yellow and
red represent wild, hybrid and mutation type, respectively. a, b, c and
d the corresponding scatter plots of A, B, C and D showing the geno-
type assignment. Each scatter spot shows the signal intensities from
each sample without correction for the average local background signal
from the microarrays. The scatter spots close to the longitudinal (y)
axis indicate the wild homozygote and those close to the lateral (x) axis
indicate the mutational homozygote. The spots far from the x axis and
the y axis indicated the heterozygote
Cancer Chemother Pharmacol (2010) 65:437–446 441
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Results
Images of DNA-microarray hybridization 
for SNPs genotyping
On the basis of the immobilization eYciency, acryl-modiWed
glass slides were selected to fabricate DNA microarrays. By
allele-speciWc oligonucleotide dual-color Xuorescence hybrid-
ization, homozygous wild type, homozygous mutant type, and
heterozygote type yielded green, red, and yellow Xuorescence,
respectively. Figure 1 showed the microarray images.
Sequencing result
Sequencing of 10% samples randomly selected was per-
formed. The result was 100% concordance to that of the
genotyping suggesting that the 3-D DNA microarray
method is reliable.
Treatment response and genotype
Of 113 patients, 30 (26.5%) had some responses (CR+PR)
and 83 (73.5%) showed no response (SD+PD).
Table 3 shows the frequencies of genotypes in diVerent
response patients, and the association of genotypes with the
treatment response. (1) Genotype frequencies for both MRP2
and GSTP1 polymorphisms were found to be in Hardy–
Weinberg equilibrium (HWE). Allele frequencies and HWE
of each locus were shown in Tables 4 and 5. (2) The poly-
morphic genotypes of MRP2 (C-24T) and GSTP1
(Ile105Val) were signiWcantly diVerent between patients who
responded and did not respond to the platinum-based treat-
ment. After combining the heterozygous and homozygous
variant genotypes, the diVerence remained statistically sig-
niWcant, suggesting that MRP2 (C-24T) and GSTP1
(Ile105Val) genotype diVered between the two groups. (3)
Genotype inXuences the treatment response. Patients carry-
ing at least one variant allele (MRP2-C-24T C/T+T/T and
GSTP1 A/G+G/G) were more likely to be responders com-
pared with those who did not carry the variant allele; after
adjusting for patient gender, age at diagnosis, tumor histol-
ogy, disease stage, and chemotherapy regimens, the OR for
response were 4.493 and 2.881, and the 95% CI were
between 1.728 and 11.682 (P = 0.002), and between 1.167
and 7.113 (P = 0.022), respectively. For other SNPs locus,
however, the genotypes were not substantially diVerent
between the groups. (4) Table 6 displays statistics from case–
control tests performed on each individual haplotype of
MRP2 (C-24T) and GSTP1 (Ile105Val). A signiWcant P
value indicates that there is an association between the
Table 3 Genotype and response to chemotherapy among NSCLC patients (n = 113)
Adjusted OR (95% CI): OR (95% CI) after adjusting for patient gender, age at diagnosis, tumor histology, disease stage, and chemotherapy
regimens
Genotype Cases Response to chemotherapy OR (95% CI) P value Adjusted OR (95% CI) Adjusted 
P value
CR + PR (%) n = 30 SD + PD (%) n =8 3
MRP2 (C-24T)
C/C 66 11 (36.7) 55 (66.3) 1 0.015 4.069 (1.518–10.910) 0.005
C/T 43 16 (53.3) 27 (32.5) 2.959 (1.211–7.246) 0.023 10.514 (0.842–131.319) 0.068
T/T 4 3 (10.0) 1 (1.2) 14.925 (1.425–166.667) 0.005 4.493 (1.728–11.682) 0.002
C/T+T/T 47 19 (63.3) 28 (33.7) 3.390 (1.420–8.130)
MRP2 (Val417Ile)
G/G 84 20 (66.7) 64 (77.1) 1
G/A 26 9 (30.0) 17 (20.5) 1.695 (0.654–4.386) 0.274 1.910 (0.697–5.229) 0.208
A/A 3 1 (3.3) 2 (2.4) 1.600 (0.138–18.519) 0.568 1.616 (0.115–22.779) 0.722
G/A+A/A 29 10 (33.3) 19 (22.9) 1.684 (0.674–4.202) 0.262 1.879 (0.710–4.968) 0.204
MRP2 (Ile1324Ile)
C/C 74 20 (66.7) 54 (65.1) 1
C/T 33 8 (26.7) 25 (30.1) 0.864 (0.335–2.227) 0.762 1.066 (0.385–2.951) 0.901
T/T 6 2 (6.7) 4 (4.8) 1.350 (0.229–7.937) 0.665 1.508 (0.210–10.830) 0.683
C/T+T/T 39 10 (33.3) 29 (34.9) 0.931 (0.385–2.252) 0.874 1.133 (0.441–2.911) 0.796
GSTP1 (Ile105Val)
A/A 71 13 (43.3) 58 (69.9) 1
A/G 38 15 (50.0) 23 (27.7) 2.907 (1.200–7.042) 0.016 2.788 (1.106–7.029) 0.030
G/G 4 2 (6.7) 2 (2.4) 4.464 (0.574–34.483) 0.176 4.083 (0.457–36.463) 0.208
A/G+G/G 42 17 (56.7) 25 (30.1) 3.030 (1.282–7.194) 0.010 2.881 (1.167–7.113) 0.022Cancer Chemother Pharmacol (2010) 65:437–446 443
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haplotype C-A (MRP2-24C and GSTP1105A) and the treat-
ment response. The patients carrying MRP2-24C and
GSTP1105A simultaneously were more to be non-responders.
Discussion
One of the major obstacles of cancer chemotherapy is the
development of drug resistance, which prevents the appli-
cation of suYcient high doses to eradicate less-sensitive
tumor cell populations. Interindividual diVerences in
response to xenobiotics, which include many clinically
used drugs, are extensive and represent a major problem in
rational therapeutics. Such diVerences in many cases may
be caused by inherited diVerences in enzymes and trans-
porters, which function in drug elimination [24]. Owing to
its possible eVect on gene expression, we anticipated that
polymorphisms of drug metabolizing enzymes genes and
drug transporters genes may inXuence tumor response to
platinum-based chemotherapy. The identiWcation of molec-
ular variables that predict either sensitivity or resistance to
chemotherapy is of major interest in selecting the most
likely eVective Wrst-line treatment.
Some studies suggested that there is no diVerence
whether cisplatin- or carboplatin-based chemotherapy regi-
mens in the clinical eYcacy [25, 26]. Moreover, the results
tend to be similar whether the partner drug is paclitaxel,
docetaxel, or gemcitabine. Similar results are generally
obtained with carboplatin [25–27]. Hence, the data of these
113 patients were analyzed as a combination group.
Glutathione  S-transferases are crucial for the cell
defence system. These phase II detoxiWcation enzymes are
involved in the detoxiWcation of a variety of chemothera-
peutics including platinum. In vitro analyses revealed a sig-
niWcant association between high GSTP1 expression of
tumor cells and decreased sensitivity to platinum agents
[28]. Cisplatin is detoxiWed by glutathione through adduct
formation [29]. GSTP1 interacts with platinum-based com-
pounds [30], and glutathione-conjugated platinum can be
quickly eZuxed from cells [31]. Thus, it is plausible that
high GST activity may result in more rapid drug metabo-
lism that diminishes the cytotoxic eVects of chemotherapy
on tumor cells [32].
Multidrug resistance-associated protein 2 is responsible
for the intracellularly formed glucuronide and GSH conju-
gates of clinically important drugs. MRP2 is expressed in
many tumor tissues, and the tumor cells overexpressing
MRP2 might acquire the multidrug resistance [18]. A sig-
niWcant correlation has been observed between MRP2
mRNA levels and cisplatin resistance in colorectal carci-
noma [33] suggesting that MRP2 contributes to resistance
against treatment with the chemotherapeutic drugs.
Because the important factors inXuencing interindividual
diVerences in the drug disposition, many analyses of SNPs
of drug metabolizing enzymes and drug transporters have
been performed.
Table 4 Allele frequencies
Locus Allele Frequency Standard 
Error
95% CI
MRP2 (C-24T) C 0.7743 0.0265 0.7168–0.8230
T 0.2257 0.0265 0.1770–0.2832
MRP2 (Val417Ile) A 0.1416 0.0238 0.0973–0.1903
G 0.8584 0.0238 0.8097–0.9027
MRP2 (Ile1324Ile) C 0.8009 0.0277 0.7434–0.8540
T 0.1991 0.0277 0.1460–0.2566
GSTP1 (Ile105Val) A 0.7965 0.0263 0.7434–0.8451
G 0.2035 0.0263 0.1549–0.2566
Table 5 Genotype frequencies Locus Genotype Frequency HWD coeV Standard error 95% CI
MRP2 (C-24T) C/C 0.5841 ¡0.0155 0.0151 ¡0.0459–0.0149
C/T 0.3805 ¡0.0155 0.0151 ¡0.0459–0.0149
T/T 0.0354 ¡0.0155 0.0151 ¡0.0459–0.0149
MRP2 (Val417Ile) A/A 0.0265 0.0065 0.0126 ¡0.0165–0.0318
A/G 0.2301 0.0065 0.0126 ¡0.0165–0.0318
G/G 0.7434 0.0065 0.0126 ¡0.0165–0.0318
MRP2 (Ile1324Ile) C/C 0.6549 0.0135 0.0163 ¡0.0185–0.0484
C/T 0.2920 0.0135 0.0163 ¡0.0185–0.0484
T/T 0.0531 0.0135 0.0163 ¡0.0185–0.0484
GSTP1 (Ile105Val) A/A 0.6283 ¡0.0060 0.0146 ¡0.0313–0.0218
A/G 0.3363 ¡0.0060 0.0146 ¡0.0313–0.0218
G/G 0.0354 ¡0.0060 0.0146 ¡0.0313–0.0218444 Cancer Chemother Pharmacol (2010) 65:437–446
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Board et al. [34]  Wrst identiWed the GSTP1 polymor-
phisms. Alterations in the structure, function, or expression
levels of GSTP1 due to genetic polymorphisms could alter
the ability to detoxify chemotherapeutic agents and modulate
drug response. The Ile105Val GSTP1 polymorphism, an A/
G SNP located within the substrate binding domain of
GSTP1 at position +313 within exon 5 results in an amino
acid substitution of isoleucine by valine at codon 105 of the
enzyme. This substitution has been shown to signiWcantly
inXuence the catalytic activity and thermal stability of the
enzyme and to aVect the conjugation capacity of GSTP1 for
certain substrates, including platinum agents [35, 36]. Rather
than being present or absent, the GSTP1 gene has alleles that
encode enzymes with diVerent activities. The highest level of
GSTP1 activity is seen in individuals with homozygous wild
genotype (Ile/Ile). The activity is somewhat reduced in het-
erozygotes (Ile/Val) and further diminished for those with
homozygous mutant genotype (Val/Val) [35]. It is estimated
that approximately 50% of people have either one or two
valine alleles (Ile/Val or Val/Val) [37]. Thus, this polymor-
phism is linked to clinical outcome of patients who received
platinum-based chemotherapy [38,  39]. Individuals with
these variant GSTP1 genotypes that result in reduced GST
enzymatic activity may be good responders due to decreased
detoxiWcation of chemotherapeutic agents.
Based on this, we hypothesize that lung cancer patients
with GSTP1 Ile105Val polymorphisms conferring low
activity may have a more favorable prognosis. Our result
conWrmed this hypothesis. We suggest that this might occur
due to the reduced metabolism and slower removal of che-
motherapeutic agents, which would yield a prolonged cyto-
toxic eVect; this could lead to a better treatment response
and subsequently improved patient survival. Homozygous
mutants of GSTP1 (Ile105Val) showed no eVect on treat-
ment response, probably the numbers were too small to
identify such an eVect. Therefore, we are enlarging the
samples to conWrm the results.
The MRP2 gene is located on chromosomal locus 10q24
and consists of 32 exons (31 coding exons) and spans 69 kb.
SNP analysis of MRP2 has been performed, and numerous
SNPs have been identiWed [40, 41]. A recent study provided
detailed information on ABCC2 variations and haplotype
structures in Japanese [42]. Because of its importance in
determining the disposition of anionic drugs, and as a conse-
quence, in determining the pharmacological and/or adverse
eVects of substrate drugs, correlations between genotype
and phenotype need to be established [40]. However,
although several studies have suggested the association of
SNPs with altered MRP2 expression or function, knowledge
about biochemical consequences is still very poor and their
association with clinical phenotype remains to be clariWed.
The functional analysis of these SNPs mutants of MRP2 still
remains to be performed. Among several kinds of MRP2
SNPs, C-24T (promoter), G1249A (exon 10) and C3972T
(exon 28) are frequently observed [41, 43]. Their allele fre-
quency is 18.8, 12.5, and 21.9%, respectively. In this paper,
the allele frequency found in this population is 22.6, 14.2,
and 19.9%, respectively, which is similar to the literature.
G1249A polymorphism is a G!A base change that results
in amino acid alterations from Val to Ile at 417, and 1,249
AA is associated with decreased mRNA [44]; whereas
C3972T is the ‘silent’ mutation at 1,324 (Ile1324Ile). sev-
eral studies have suggested their association with altered
MRP2 expression or function [45, 46]. Besides being able to
quickly export glutathione-conjugated platinum, upregu-
lated expression of MRP2 is also associated with decreased
formation of platinum-DNA adducts and decreased G2-
arrest in the cisplatin-resistant cell lines [47]. Amino acid
substitution due to SNPs might weaken this eVectiveness,
and therefore, might enhance the sensitivity to platinating
agents. Yang et al. [48] reported that variant in exon 10
(G1249A) was signiWcantly correlated with response to che-
motherapy. We also have analyzed these three frequent
SNPs in MRP2 gene to investigate their signiWcance in
chemosensitivity to platinum-based chemotherapy. DiVerent
from Yang’s result, however, our results indicate that the
mutant alleles in promoter (C-24T) was signiWcantly related
to sensitiveness of NSCLC to therapeutic agents, while the
SNPs in exon 10 (G1249A) and exon 28 (C3972T) were not
associated with response to chemotherapy. In this study, the
presence of the A allele in exon 10 showed a similar trend of
better response. However, it is statistically impossible to
Wnd the diVerences of the chemotherapeutic eYcacy among
variant genotype. We think that there should exist other
Table 6 Tests for haplotype-trait association between MRP2 (C-24T) and GSTP1 (Ile105Val)
Trait response to chemotherapy, Trait 1 SD+PD n = 83, Trait 2 CR+PR n =3 0
Haplotype Frequencies 95% CI Chi-square P value Prob Exact
Trait 1 Trait 2 Combined
C–A 0.71074 0.43370 0.64446 0.58192–0.70701 14.8140 0.0001 <0.0001
C–G 0.11456 0.19963 0.12987 0.08595–0.17380 2.9280 0.0871 0.1600
T–A 0.12661 0.24963 0.15200 0.10509–0.19891 5.2672 0.0217 0.0500
T–G 0.04809 0.11703 0.07367 0.03953–0.10780 3.2455 0.0716 0.1400Cancer Chemother Pharmacol (2010) 65:437–446 445
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mechanisms that contribute to the complicacy of the result.
For example, most MRP2 substrates are also transported by
OATP2 (organic anion transporting polypeptide), so the
SNPs and/or inter-individual diVerences in the expression
level of OATP2 maybe also need to be analyzed simulta-
neously.
Our observation suggests that the polymorphic status of
GSTP1 Ile105Val and MRP2 C-24T might predict treat-
ment response of advanced stage NSCLC patients. More-
over, there is an association between the haplotype C-A
(MRP2 -24C and GSTP1 105A) and the response to che-
motherapy. However, the limitation of our study must be
acknowledged. Usually, in the retrospective study, it may
be more precise and objective to evaluate the overall sur-
vival and progression-free survival as prognostic factors.
Considering the diYculty in clinical practice, we chose che-
motherapy response as end point of prediction, which was
also critical to illuminate the mechanism aVected outcome.
Ideally, validation studies should be carried out to measure
such parameters as predictive and prognostic factors which
is also the expected aim of our next research. Therefore,
larger sample size and prospective studies, the independent
collection of clinical outcomes data and genotyping, and in
vivo functional studies are needed to conWrm the results
and identify the clear biological basis of these Wndings.
Here, we used a new gel-based DNA microarray geno-
typing method, reported by Xiao et al. [23], for gene muta-
tion analysis and functional SNP screening. This method
based on Rehman’s idea [49]was improved and gave a uni-
form sample concentration and viscosity for all of the spots
on microarrays during spotting, and had a much lower Xuo-
rescent background as well as higher S/N (signal/noise).
According to the report, by modifying the process for
immobilization of nucleic acids, a high quantity microarray
with a uniform sample concentration of spots is fabricated.
The gel immobilization of nucleic acids has a high immobi-
lization yield and good hybridization eYciency. PCR prod-
ucts modiWed with acrylamide groups can be used in
parallel for gel immobilization to prepare the microarray, in
which PCR products are puriWed only by ethanol precipita-
tion or even untreated. As an alterative to conventional
washing, electrophoresis eVectively removed the non-spe-
ciWcally bound targets in hybridization and therefore reduce
the high background after hybridization, so that the power
for discriminating single-nucleotide mismatch is signiW-
cantly enhanced. DiVerent genotypes of an SNP have suc-
cessfully been determined by the ratio of signal intensities
from two allele-speciWc oligonucleotides labeled with
diVerent dyes. When compared with the common used
genotyping methods, such as TagMan assay, PCR–RFLP
(restriction fragment length polymorphism), this method is
simple, rapid, robust, eYcient, and cost-eVective for the
detection of single-nucleotide mismatch, extremely power-
ful in genotyping of large-scale samples, and could be used
with high reproducibility [23, 50, 51].
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